Oral Oncology
Volume 45, Issue 1 , Pages 23-29 , January 2009

Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer

  • Anna Ansell

      Affiliations

    • Division of Otorhinolaryngology, University Hospital, SE-58185 Linköping, Sweden
    • ,
  • Lovisa Farnebo

      Affiliations

    • Division of Otorhinolaryngology, University Hospital, SE-58185 Linköping, Sweden
    • ,
  • Reidar Grénman

      Affiliations

    • Department of Otorhinolaryngology, Head & Neck Surgery, and Medical Biochemistry, University of Turku, Finland
    • ,
  • Karin Roberg

      Affiliations

    • Division of Otorhinolaryngology, University Hospital, SE-58185 Linköping, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 13 221534.
    • ,
  • Lena K Thunell

      Affiliations

    • Division of Cell Biology, Department of Biomedicine and Surgery, Linköping University, Sweden

Received 23 January 2008 ,Revised 12 March 2008 ,Accepted 13 March 2008.

References 

  1. Shah JP, Lydiatt W. Treatment of cancer of the head and neck. CA Cancer J Clin. 1995;45:352–368
  2. Friedman NR. Prognostic factors for local recurrence, metastases, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol. 1993;28:281–282
  3. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7:165–197
  4. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995;11:462–464
  5. Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78:335–342
  6. Da Costa Andrade VC, Parise O, Hors CP, de Melo Martins PC, Silva AP, Garicochea B. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol. 2007;82:53–57
  7. Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002;62:840–847
  8. Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004;10:6169–6178
  9. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer. 2004;111:213–217
  10. Morimoto Y, Ozaki T, Ouchida M, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003;98:2245–2250
  11. Mawrin C, Kirches E, Diete S, et al. Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas. Cancer Lett. 2006;239:239–245
  12. Spinola M, Leoni VP, Tanuma J, et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep. 2005;14:415–419
  13. Matakidou A, El Galta R, Rudd MF, et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer. 2007;96:1904–1907
  14. Nilsson JA, Hedberg JJ, Vondracek M, et al. Alcohol dehydrogenase 3 transcription associates with proliferation of human oral keratinocytes. Cell Mol Life Sci. 2004;61:610–617
  15. Grenman R, Carey TE, McClatchey KD, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer. 1991;67:2741–2747
  16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275
  17. Thussbas C, Nahrig J, Streit S, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006;24:3747–3755
  18. Elander N, Soderkvist P, Fransen K. Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res. 2006;26:791–795
  19. Hettiaratchi A, Hawkins NJ, McKenzie G, et al. The collagenase-1 (MMP-1) gene promoter polymorphism – 1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer. 2007;96:783–792
  20. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003;25:654–661
  21. Couture C, Raybaud-Diogene H, Tetu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94:713–722
  22. Mandic R, Schamberger CJ, Muller JF, et al. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res. 2005;11:6845–6852
  23. Noutomi T, Chiba H, Itoh M, Toyota H, Mizuguchi J. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol. 2002;38:41–48
  24. Pekkola-Heino K, Jaakkola M, Kulmala J, Grenman R. Comparison of cellular radiosensitivity between different localizations of head and neck squamous-cell carcinoma. J Cancer Res Clin Oncol. 1995;121:452–456
  25. Erjala K, Pulkkinen J, Kulmala J, Grenman R. Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro. Acta Oncol. 2004;43:169–174

PII: S1368-8375(08)00093-6

doi: 10.1016/j.oraloncology.2008.03.007

Oral Oncology
Volume 45, Issue 1 , Pages 23-29 , January 2009

Article Tools

* Image Usage & Resolution